Gordian Bio Releases Preprint on Scalable In Vivo Mosaic Screening

Got story updates? Submit your updates here. ›

Gordian Biotechnology, a biotechnology company focused on discovering and validating therapeutic targets through causal biology, has announced the release of a new preprint detailing its 'Multispecies, Modality-Agnostic Scalable In Vivo Mosaic Screening Platform for Therapeutic Target Discovery'.

Why it matters

Gordian's new screening platform could help advance the discovery and validation of novel therapeutic targets, which is crucial for developing new treatments for a wide range of diseases. The ability to conduct scalable in vivo testing across multiple species is an important step forward in the field of causal biology.

The details

Gordian's preprint outlines a new screening platform that enables the company to conduct scalable in vivo testing across multiple species to discover and validate therapeutic targets. This modality-agnostic approach allows Gordian to explore a broader range of potential targets compared to traditional methods.

• The preprint was released on March 4, 2026.